The difference emerged during follow-up beyond six months, and no significant difference between the two drugs was established for cardiovascular disease risk, although the limited number of cardiovascular events reduced the precision of these estimates
CrossRef TwoStep Machine Learning Model Enhances Identification of HighRisk Metabolic DysfunctionAssociated Steatotic Liver Disease Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiongyue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye, Chunyan Ye, Xiaoming Chen, Meijie Chen, Jiale Niu, Yangyang Xie, Kaixin Chang, Jiakun Miao, Weili Liu, Junping Shi, Zhongjie Hu, Minghua Liver International .2026;[Epub] CrossRef Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study Semiu O
Similarly, patients who received semaglutide were less likely to have acute myocardial infarction (5.2% [5,764] vs
population received a prescription for semaglutide in 2023
Yang J, Park OJ, Kim J, Han S, Yang Y, Yun CH, et al